Cargando…

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease

PURPOSE: Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rate of approximately 11 mL/min. METHODS: Pharmacokinetic parameters, including dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krens, L. L., Baas, J. M., Guchelaar, H. J., Gelderblom, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754392/ https://www.ncbi.nlm.nih.gov/pubmed/29170802 http://dx.doi.org/10.1007/s00280-017-3479-2

Ejemplares similares

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
por: Baas, J. M., et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
por: Ketzer, Sander, et al.
Publicado: (2017)

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab
por: Baas, Jara, et al.
Publicado: (2018)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
por: Burris, Howard, et al.
Publicado: (2011)

Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study
por: Krens, Lisanne L., et al.
Publicado: (2014)

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
por: Raimondi, A., et al.
Publicado: (2021)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
por: Yip, Pui Lam, et al.
Publicado: (2023)

Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer
por: Souwer, E. T. D., et al.
Publicado: (2023)

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer
por: de Wit, D., et al.
Publicado: (2016)

Immunogenicity of panitumumab in combination chemotherapy clinical trials
por: Weeraratne, Dohan, et al.
Publicado: (2011)

Patient considerations in metastatic colorectal cancer – role of panitumumab
por: Rogers, Jane E
Publicado: (2017)

Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
por: Liao, Michael Z, et al.
Publicado: (2020)

Assessment of the cardiac safety between cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory mCRC
por: Tang, Xue-miao, et al.
Publicado: (2017)

Fatal interstitial lung disease caused by Panitumumab-containing chemotherapy regimen
por: Al-asadi, Osamah, et al.
Publicado: (2018)

Pharmacokinetics in children with chronic kidney disease
por: Schijvens, Anne M., et al.
Publicado: (2019)

Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti‐HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients
por: Lorant, Tomas, et al.
Publicado: (2018)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015)

The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials
por: Liang, Ruo-feng, et al.
Publicado: (2015)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx, Jeroen J M A, et al.
Publicado: (2020)

The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies
por: Wang, Chengchen, et al.
Publicado: (2020)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
por: Watanabe, Shoichi, et al.
Publicado: (2017)

Panitumumab-Induced Acneiform Rash in a Patient with Metastatic Colon Adenocarcinoma
por: Martins-Filho, Paulo Ricardo Saquete, et al.
Publicado: (2013)

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
por: López-Gómez, Miriam, et al.
Publicado: (2012)

Fluorouracil/oxaliplatin/panitumumab: Lack of efficacy: case report
Publicado: (2022)

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Population pharmacokinetics and dose optimisation of colecalciferol in paediatric patients with chronic kidney disease
por: Wan, Mandy, et al.
Publicado: (2021)

Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients(†)
por: Boku, Narikazu, et al.
Publicado: (2014)

Pharmacokinetics of metformin in patients with chronic kidney disease stage 4 and metformin‐naïve type 2 diabetes
por: Dissanayake, Ajith M., et al.
Publicado: (2018)

Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
por: Taniguchi, Hiroya, et al.
Publicado: (2018)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
por: Bennett, L, et al.
Publicado: (2011)

The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis
por: Chen, Qiang, et al.
Publicado: (2016)

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab
por: Odom, Dawn, et al.
Publicado: (2010)

Panitumumab-Induced Eruptive Seborrhoeic Keratosis in a Patient with Metastatic Colorectal Cancer
por: Koumaki, Dimitra, et al.
Publicado: (2020)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2l2qu6k9qvudando6u5nv42e24